Dr. Reddy’s Laboratories Ltd announced that it has launched paricalcitol injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar (paricalcitol) injection in the United States market approved by the US Food & Drug Administration (USFDA).

The Zemplar brand and generic had US sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.

Dr. Reddy’s paricalcitol injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.

Zemplar is a registered trademark of ABBVIE Inc.